灵活丁丙诺啡/纳洛酮治疗处方阿片使用障碍的非劣效随机试验
该研究为七中心、24周、实用、开放标签、非劣效、双臂平行随机对照试验,纳入272例处方类阿片使用障碍成人,比较灵活带回家丁丙诺啡/纳洛酮与密切监督美沙酮。主要结局为24周内阿片阴性尿检比例,丁丙诺啡/纳洛酮组24.0% vs 美沙酮组18.5%,调整均值差5.6%(95%CI=-0.3, +∞),达到非劣效。丁丙诺啡/纳洛酮组保留治疗的OR为0.47(95%CI=0.24, 0.90)。
要点
- 丁丙诺啡/纳洛酮灵活模式在减少阿片使用方面非劣效于美沙酮。
- 丁丙诺啡/纳洛酮组阿片阴性尿检比例24.0% vs 美沙酮组18.5%。
- 丁丙诺啡/纳洛酮组保留治疗OR为0.47(95%CI=0.24, 0.90)。
核心结论
- 丁丙诺啡/纳洛酮灵活模式安全且非劣效于美沙酮减少处方类阿片使用障碍者的阿片使用。
研究设计与样本
- 七中心、泛加拿大、24周、实用、开放标签、非劣效、双臂平行随机对照试验,纳入272例处方类阿片使用障碍成人。
- 参与者按1:1随机分配至舌下丁丙诺啡/纳洛酮(目标剂量8mg/2mg至24mg/6mg/日,灵活带回家给药)或口服美沙酮(约60-120mg/日,密切监督)。
- 主要分析为改良意向性分析,排除随机后不久死亡1例,所有随机参与者均纳入分析。
主要发现
- 丁丙诺啡/纳洛酮组阿片阴性尿检平均比例24.0%(SD=34.4) vs 美沙酮组18.5%(SD=30.5),调整均值差5.6%(95%CI=-0.3, +∞)。
- 丁丙诺啡/纳洛酮组保留在指定治疗的OR为0.47(95%CI=0.24, 0.90),相比美沙酮组。
- 共报告24例药物相关不良事件:丁丙诺啡/纳洛酮组12例(8/138,5.7%),美沙酮组12例(12/134,9.0%),主要包括戒断、性腺功能减退和过量。
关键数值与推荐
- 非劣效界值为15%。
- 丁丙诺啡/纳洛酮目标剂量8mg/2mg至24mg/6mg/日,灵活带回家给药;美沙酮约60-120mg/日,密切监督。
临床怎么用
- 丁丙诺啡/纳洛酮灵活模式可扩大阿片激动剂治疗的可及性,并减少阿片过量危机背景下的伤害。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Extensive exposure to prescription-type opioids has resulted in major harm worldwide, calling for better-adapted approaches to opioid agonist therapy. The authors aimed to determine whether flexible take-home buprenorphine/naloxone is as effective as supervised methadone in reducing opioid use in prescription-type opioid consumers with opioid use disorder. METHODS: This seven-site, pan-Canadian, 24-week, pragmatic, open-label, noninferiority, two-arm parallel randomized controlled trial involved treatment-seeking adults with prescription-type opioid use disorder. Participants were randomized in a 1:1 ratio to treatment with sublingual buprenorphine/naloxone (target dosage, 8 mg/2 mg to 24 mg/6 mg per day; flexible take-home dosing) or oral methadone (≈60-120 mg/day; closely supervised). The primary outcome was the proportion of opioid-free urine drug screens over 24 weeks (noninferiority margin, 15%). All randomized participants were analyzed, excluding one who died shortly after randomization, for the primary analysis (modified intention-to-treat analysis). RESULTS: Of 272 participants recruited (mean age, 39 years [SD=11]; 34.2% female), 138 were randomized to buprenorphine/naloxone and 134 to methadone. The mean proportion of opioid-free urine drug screens was 24.0% (SD=34.4) in the buprenorphine/naloxone group and 18.5% (SD=30.5) in the methadone group, with a 5.6% adjusted mean difference (95% CI=-0.3, +∞). Participants in the buprenorphine/naloxone group had 0.47 times the odds (95% CI=0.24, 0.90) of being retained in the assigned treatment compared with those in the methadone group. Overall, 24 drug-related adverse events were reported (12 in the buprenorphine/naloxone group [N=8/138; 5.7%] and 12 in the methadone group [N=12/134; 9.0%]) and mostly included withdrawal, hypogonadism, and overdose. CONCLUSIONS: The buprenorphine/naloxone flexible model of care was safe and noninferior to methadone in reducing opioid use among people with prescription-type opioid use disorder. This flexibility could help expand access to opioid agonist therapy and reduce harms in the context of the opioid overdose crisis.
引用
- Jutras-Aswad D, Le Foll B, Ahamad K, et al. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. Am J Psychiatry. 2022. PMID: 35702828. doi:10.1176/appi.ajp.21090964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。